Dermira (NASDAQ:DERM) Stock Rating Upgraded by BidaskClub

Dermira (NASDAQ:DERM) was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report released on Thursday, BidAskClub reports.

Other equities analysts have also recently issued research reports about the company. Zacks Investment Research raised Dermira from a “hold” rating to a “buy” rating and set a $8.50 price objective for the company in a report on Wednesday, February 20th. HC Wainwright started coverage on Dermira in a report on Thursday, February 14th. They issued a “buy” rating and a $13.00 price objective for the company. Citigroup boosted their price objective on Dermira from $15.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, March 19th. Needham & Company LLC reissued a “buy” rating and issued a $22.00 price objective (up previously from $16.00) on shares of Dermira in a report on Monday, March 25th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $20.00 price objective on shares of Dermira in a report on Tuesday, April 2nd. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $17.97.

Shares of DERM stock opened at $9.43 on Thursday. The company has a current ratio of 7.13, a quick ratio of 6.92 and a debt-to-equity ratio of 4.36. Dermira has a 52-week low of $6.00 and a 52-week high of $15.48.

Dermira (NASDAQ:DERM) last issued its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($1.49) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.10) by ($0.39). The company had revenue of $2.45 million during the quarter, compared to analyst estimates of $2.63 million. Dermira had a negative net margin of 510.47% and a negative return on equity of 391.86%. As a group, analysts predict that Dermira will post -5.2 EPS for the current fiscal year.

In related news, insider Eugene A. Bauer sold 35,000 shares of the company’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $15.00, for a total value of $525,000.00. Following the completion of the transaction, the insider now owns 43,900 shares of the company’s stock, valued at approximately $658,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 14.80% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Fifth Third Bancorp acquired a new position in Dermira in the 1st quarter worth about $44,000. Advisor Group Inc. raised its holdings in Dermira by 117.0% in the 1st quarter. Advisor Group Inc. now owns 6,062 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 3,269 shares during the period. BNP Paribas Arbitrage SA raised its holdings in Dermira by 48,273.3% in the 1st quarter. BNP Paribas Arbitrage SA now owns 7,256 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 7,241 shares during the period. Nisa Investment Advisors LLC raised its holdings in Dermira by 2,500.0% in the 1st quarter. Nisa Investment Advisors LLC now owns 10,400 shares of the biopharmaceutical company’s stock worth $141,000 after purchasing an additional 10,000 shares during the period. Finally, Metropolitan Life Insurance Co. NY raised its holdings in Dermira by 356.7% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 12,912 shares of the biopharmaceutical company’s stock worth $93,000 after purchasing an additional 10,085 shares during the period. 93.92% of the stock is owned by institutional investors.

Dermira Company Profile

Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.

Recommended Story: How Buying a Call Option Works

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.